tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Heart Failure D006333 36 associated lipids
Angioedema D000799 6 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Hydronephrosis D006869 4 associated lipids
Trypanosomiasis D014352 5 associated lipids
Alopecia D000505 14 associated lipids
Liver Diseases D008107 31 associated lipids
Corneal Diseases D003316 13 associated lipids
Testicular Diseases D013733 15 associated lipids
Facial Dermatoses D005148 7 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Schmidt LE et al. Relationship between postoperative erythromycin breath test and early morbidity in liver transplant recipients. 2003 Transplantation pmid:12883193
Burroughs TE et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. 2007 Transplantation pmid:17452891
Neuhaus P et al. Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience. 1995 Transplantation pmid:7530868
Moss MC et al. Lithium use for bipolar disorder post renal transplant: is mood stabilization without toxicity possible? 2014 Transplantation pmid:24492429
Fridell JA et al. Steroid withdrawal for pancreas after kidney transplantation in recipients on maintenance prednisone immunosuppression. 2006 Transplantation pmid:16906038
Misra S et al. Red cell aplasia in children on tacrolimus after liver transplantation. 1998 Transplantation pmid:9500636
Narayanan M et al. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression. 2013 Transplantation pmid:23423268
Reutzel-Selke A et al. Short-term immunosuppressive treatment of the donor ameliorates consequences of ischemia/ reperfusion injury and long-term graft function in renal allografts from older donors. 2003 Transplantation pmid:12811235
Takeguchi N et al. Inhibition of the multidrug efflux pump in isolated hepatocyte couplets by immunosuppressants FK506 and cyclosporine. 1993 Transplantation pmid:7681229
Bundick RV et al. FK506 as an agonist to induce inhibition of interleukin 2 production. 1992 Transplantation pmid:1374947
Egeland EJ et al. High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation. 2017 Transplantation pmid:28452920
Esquivel CO et al. Suggested guidelines for the use of tacrolimus in pediatric liver transplant patients. 1996 Transplantation pmid:8607198
Hsiau M et al. Monitoring nonadherence and acute rejection with variation in blood immunosuppressant levels in pediatric renal transplantation. 2011 Transplantation pmid:21857278
Yates CJ et al. Screening for new-onset diabetes after kidney transplantation: limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin. 2013 Transplantation pmid:23902993
Kitayama T et al. Facilitation of tacrolimus-induced heart-allograft acceptability by pretransplant host treatment with granulocyte colony-stimulating factor: interleukin-12-restricted suppression of intragraft monokine mRNA expression. 2003 Transplantation pmid:12605126
Ciancio G et al. Use of intravenous FK506 to treat acute rejection in simultaneous pancreas-kidney transplant recipients on maintenance oral FK506. 1997 Transplantation pmid:9075856
Cooper MH et al. Rapamycin but not FK506 inhibits the proliferation of mononuclear phagocytes induced by colony-stimulating factors. 1994 Transplantation pmid:7509089
Egawa H et al. Isolated alkaline phosphatemia following pediatric liver transplantation in the FK506 ERA. 1995 Transplantation pmid:7533958
Sarwal MM et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. 2001 Transplantation pmid:11468528
Camirand G et al. Combined immunosuppression of mycophenolate mofetil and FK506 for myoblast transplantation in mdx mice. 2001 Transplantation pmid:11468532
Nobori S et al. Long-term acceptance of fully allogeneic cardiac grafts by cotransplantation of vascularized thymus in miniature swine. 2006 Transplantation pmid:16421473
Yu S et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. 2006 Transplantation pmid:16421475
Macphee IA et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. 2002 Transplantation pmid:12490779
Luan FL et al. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. 2011 Transplantation pmid:21242885
Ahsan N et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. 2001 Transplantation pmid:11477347
Ho ET et al. Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review. 2013 Transplantation pmid:23542469
Shapiro R et al. Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. 2008 Transplantation pmid:18431232
Porrini E et al. Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: a prospective and multicenter study. 2008 Transplantation pmid:18431233
Veroux M et al. Impact of conversion to a once daily tacrolimus-based regimen in kidney transplant recipients with gastrointestinal complications. 2012 Transplantation pmid:22298033
Panz VR et al. Diabetogenic effect of tacrolimus in South African patients undergoing kidney transplantation1. 2002 Transplantation pmid:11889436
Charney DA et al. Plasma cell-rich acute renal allograft rejection. 1999 Transplantation pmid:10515379
Fisher NC et al. The clinical impact of nephrotoxicity in liver transplantation. 2000 Transplantation pmid:10910259
MacDonald AS Management strategies for nephrotoxicity. 2000 Transplantation pmid:10910262
Randhawa PS et al. Clinical significance of renal biopsies showing concurrent acute rejection and tacrolimus-associated tubular vacuolization. 1999 Transplantation pmid:9921801
Higgins RM et al. Conversion from tacrolimus to cyclosporine in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. 2000 Transplantation pmid:10836393
Podesser BK et al. Comparison of low and high initial tacrolimus dosing in primary heart transplant recipients: a prospective European multicenter study. 2005 Transplantation pmid:15714171
Garton T Nefazodone and cyp450 3a4 interactions with cyclosporine and tacrolimus1. 2002 Transplantation pmid:12352898
Miao G et al. Development of donor-specific immunoregulatory T-cells after local CTLA4Ig gene transfer to pancreatic allograft. 2004 Transplantation pmid:15257039
Peng Y et al. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. 2013 Transplantation pmid:23263506
Hricik DE et al. Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. 2003 Transplantation pmid:14508357
Starzl TE et al. Hepatotrophic properties in dogs of human FKBP, the binding protein for FK506 and rapamycin. 1991 Transplantation pmid:1718068
Takahashi K et al. Safety and efficacy of once-daily modified-release tacrolimus in kidney transplant recipients: interim analysis of multicenter postmarketing surveillance in Japan. 2014 Transplant. Proc. pmid:24655975
Tabasco-Minguillan J et al. Long-term insulin requirement after liver transplantation with FK 506 in American veterans. 1993 Transplant. Proc. pmid:7679839
Abu-Elmagd KM et al. Strategy of FK 506 therapy in liver transplant patients: effect of graft function. 1991 Transplant. Proc. pmid:1721272
Kusne S et al. Infections during a randomized trial comparing cyclosporine to FK 506 immunosuppression in liver transplantation. 1992 Transplant. Proc. pmid:1371626
Tanaka M et al. Tacrolimus (FK 506)-dependent tolerance after liver and heart xenotransplantation: inhibition of humoral response and acceptance of donor organs. 1996 Transplant. Proc. pmid:8623341
Platz KP et al. FK506 for primary and rescue therapy following liver transplantation. 1998 Transplant. Proc. pmid:9636570
Jang HJ et al. Tacrolimus for rescue therapy in refractory renal allograft rejection. 2000 Transplant. Proc. pmid:11119925
Morita H et al. Acceptance of skin xenografts (from guinea pig to mice) by portal venous and intravenous injections of donor hematolymphoid cells. 2000 Transplant. Proc. pmid:10715422
Rodrigo E et al. High initial blood levels of tacrolimus in overweight renal transplant recipients. 2005 Transplant. Proc. pmid:15866635
Ohara K et al. Toxicologic evaluation of FK 506. 1990 Transplant. Proc. pmid:1689910
Martínez-Castelao A et al. Arterial elasticity measurement in renal transplant patients under anticalcineurin immunosuppression. 2005 Transplant. Proc. pmid:16386539
Connelly PR Thermodynamics of interaction of FK 506-binding protein and its ligands. 1991 Transplant. Proc. pmid:1721304
Stratta RJ Late acute rejection episodes after vascularized pancreas transplantation. 1998 Transplant. Proc. pmid:9636633
Hohage H et al. Cyclosporine and tacrolimus: influence on cardiovascular risk factors. 2005 Transplant. Proc. pmid:15848615
Woo J et al. Flow cytometric analysis of lymphocyte populations and activation antigen expression in blood and lymphoid tissues of FK 506-treated rats. 1990 Transplant. Proc. pmid:1697112
Kurnatowska I et al. Tacrolimus dose and blood concentration variability in kidney transplant recipients undergoing conversion from twice daily to once daily modified release tacrolimus. 2011 Transplant. Proc. pmid:21996199
Waller JR et al. Effect of rapamycin in combination with calcineurin inhibitors, FK506 and cyclosporin, following arterial injury. 2002 Transplant. Proc. pmid:12176449
Bäckman L et al. Chronic nephrotoxicity of FK 506 after liver transplantation. 1994 Transplant. Proc. pmid:7518159
Yagihashi A et al. Changes in cell surface markers in human small bowel transplantation with FK 506. 1992 Transplant. Proc. pmid:1376522
Sakimoto H et al. Prolonged survival of hamster-to-rat pancreas xenografts by FK 506 and splenectomy. 1995 Transplant. Proc. pmid:7533394
Lewis WD et al. FK 506 rescue therapy in liver transplant recipients with drug-resistant rejection. 1991 Transplant. Proc. pmid:1721336
Weimer R et al. sCD30 and neopterin as risk factors of chronic renal transplant rejection: impact of cyclosporine A, tacrolimus, and mycophenolate mofetil. 2005 Transplant. Proc. pmid:15919463
Allers C et al. Tacrolimus, daclizumab, sirolimus, and budesonide after small bowel transplantation in order to reduce nephrotoxicity. 2002 Transplant. Proc. pmid:12034251
Aktürk S et al. Average Tacrolimus Trough Level in the First Month After Transplantation May Predict Acute Rejection. 2017 Transplant. Proc. pmid:28340806
Takayama J et al. Living related liver transplantation in patients with ABO incompatibility. 1998 Transplant. Proc. pmid:9838537
Scott JS et al. Tacrolimus: a cause of hypertrophic cardiomyopathy in pediatric heart transplant recipients? 1999 Feb-Mar Transplant. Proc. pmid:10083017
Lama R et al. Lung transplants with tacrolimus and mycophenolate mofetil: a review. 2003 Transplant. Proc. pmid:12962866
Rayes N et al. Distribution of lymphocyte subtypes in liver transplant recipients. 1997 Feb-Mar Transplant. Proc. pmid:9123103
Asfar S et al. Small bowel transplantation. 1996 Transplant. Proc. pmid:8908039
Campos HH and Abbud Filho M One-year follow-up of a Brazilian randomized multicenter study comparing tacrolimus versus cyclosporine in kidney transplantation. 2002 Transplant. Proc. pmid:12176523
San Miguel C et al. Immunosuppression Strategies in the Treatment of Hepatocellular Carcinoma in Virgen de las Nieves University Hospital. 2015 Transplant. Proc. pmid:26518930
Miura K et al. Development of the Intestinal Transplantation Model With Major Histocompatibility Complex Inbred CLAWN Miniature Swine. 2016 Transplant. Proc. pmid:27320612
Ito A et al. Induction of tolerance in rat cardiac allograft model by intrathymic injection of donor bone marrow cells. 1995 Transplant. Proc. pmid:7536974
Park JW et al. Invasive pulmonary aspergillosis after living donor liver transplantation should be eradicated or not? A case report. 2011 Jul-Aug Transplant. Proc. pmid:21839284
DiMartini A et al. Psychiatric morbidity in liver transplant patients. 1991 Transplant. Proc. pmid:1721399
Steinmueller T et al. The effect of cyclosporine vs FK 506 on glucose metabolism. 1999 Feb-Mar Transplant. Proc. pmid:10083504
Moutabarrik A et al. Effect of FK 506 and cyclosporine on the expression of IL-6 and its receptor on stimulated monocytes. 1993 Transplant. Proc. pmid:7685949
Ochiai T et al. Comparative studies on the immunosuppressive activity of FK506, 15-deoxyspergualin, and cyclosporine. 1989 Transplant. Proc. pmid:2468228
Bhaloo S and Prasad GV Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: a case report. 2003 Transplant. Proc. pmid:14611983
Iacona I et al. Mycophenolic acid in combination with FK 506: a pharmacokinetic study in piglets after small-bowel transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123489
Migita K and Eguchi K FK 506-mediated T-cell apoptosis induction. 2001 Transplant. Proc. pmid:11377532
Omoto K et al. Adverse events in renal transplantation under tacrolimus/mycophnolate mofetil immunosuppression: a single-center experience. 2002 Transplant. Proc. pmid:12176591
Aguirrezabalaga J et al. Lipid profiles in liver transplantation in patients receiving tacrolimus or cyclosporin. 2001 Feb-Mar Transplant. Proc. pmid:11267192
Gotoh M et al. Tolerance induction by liver grafting and FK 506 treatment in nonhuman primates. 1991 Transplant. Proc. pmid:1721431
Ishikawa M et al. Acetaminophen absorption test as a useful indicator of small intestinal rejection in rats. 1996 Transplant. Proc. pmid:8658911
Sanghvi A et al. FK-506 enhances cyclosporine uptake by peripheral blood lymphocytes. 1987 Transplant. Proc. pmid:2445074
Varghese Z et al. Oxidizability of low-density lipoproteins from Neoral and tacrolimus-treated renal transplant patients. 1998 Transplant. Proc. pmid:9723384
Kim YE and Eun SC Effect of FK506 ointment (Protopic) on rat skin allograft model. 2014 Transplant. Proc. pmid:24815165
Banerjee R et al. Coadministration of itraconazole and tacrolimus after thoracic organ transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267435
Shingaki S et al. Graft-versus-host Disease-free, Relapse-free Survival After HLA-identical Sibling Peripheral Blood Stem Cell Transplantation With Tacrolimus-based Graft-versus-host Disease Prophylaxis in Japanese Patients. Transplant. Proc. pmid:29407317
McManus BM et al. Impact of FK 506 on myocarditis in the enteroviral murine model. 1991 Transplant. Proc. pmid:1721463
Umbro I et al. Long-term interleukin-2 assessment after conversion from a twice-daily to once-daily tacrolimus regimen in stable kidney recipients. 2012 Transplant. Proc. pmid:22974867
Tariciotti L et al. Everolimus and Advagraf Ab Initio in Combined Liver and Kidney Transplant With Donor-Specific Antibodies: A Case Report. 2016 Transplant. Proc. pmid:27932158
Ott R et al. Conversion from tacrolimus to Neoral in liver and kidney transplant recipients. 2001 Nov-Dec Transplant. Proc. pmid:11750359
Badiou S et al. Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications? 2006 Transplant. Proc. pmid:16980076
Goto S et al. Effect of FK 506 and cyclosporine on heart allograft survival in rats. 1991 Transplant. Proc. pmid:1703700
White SA et al. Influence of delayed graft function in renal transplants from cadaveric or non-heart-beating donors. 2000 Transplant. Proc. pmid:10701018
Sens YA et al. Posttransplant diabetes mellitus in renal transplant patients with hepatitis C virus. 2004 Transplant. Proc. pmid:15194304
Kliem V et al. Tacrolimus for steroid- and OKT3-resistant rejection in kidney recipients. 1998 Transplant. Proc. pmid:9636509